PDS Biotechnology Corp (PDSB)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Frank K. Bedu-Addo
Employees:
20
303A COLLEGE ROAD EAST, PRINCETON, NJ 08540
800-208-3343

PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.

Data derived from most recent annual or quarterly report
Market Cap 165.63 Million Shares Outstanding28.459 Million Avg 30-day Volume 400.325 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.26
Price to Revenue0.0 Debt to Equity0.4951 EBITDA-29.172 Million
Price to Book Value1.7961 Operating Margin0.0 Enterprise Value36.181 Million
Current Ratio15.371 EPS Growth-1.02 Quick Ratio14.799
1 Yr BETA 1.8916 52-week High/Low 13.65 / 2.89 Profit Margin0.0
Operating Cash Flow Growth-79.8168 Altman Z-Score0.1108 Free Cash Flow to Firm -21.025 Million
Earnings Report2023-03-28
View SEC Filings from PDSB instead.

View recent insider trading info

PDS Biotechnology Corp YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PDSB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PDSB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-06 by BROWN SPENCER D.
  • 4: filed on 2023-01-06 by HILL MATTHEW C
  • 4: filed on 2023-01-06 by CONN GREGORY
  • 4: filed on 2023-01-06 by BEDU-ADDO FRANK
  • 4: filed on 2023-01-06 by WOOD LAUREN
  • 4: filed on 2022-12-02 by BEDU-ADDO FRANK
  • 4: filed on 2022-06-29 by GLOVER STEPHEN C.
  • 4: filed on 2022-06-29 by ILIEV ILIAN
  • 4: filed on 2022-06-29 by BRAWLEY OTIS W
  • 4: filed on 2022-06-29 by FREITAG GREGORY GENE

    • Events (8k)

  • 8-K: filed on 2023-03-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-16:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HILL MATTHEW C CHIEF FINANCIAL OFFICER

    • Officer
    		 161,200 2023-01-05 1

    WOOD LAUREN CHIEF MEDICAL OFFICER

    • Officer
    		 110,800 2023-01-05 1

    CONN GREGORY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 137,200 2023-01-05 1

    BEDU-ADDO FRANK PRESIDENT/CEO

    • Officer
    • Director
    		 385,300 2023-01-05 2

    BROWN SPENCER D. SENIOR VP, GENERAL COUNSEL

    • Officer
    		 20,400 2023-01-05 3

    BRAWLEY OTIS W

    • Director
    		 9,000 2022-06-28 1

    GLOVER STEVE C

    • Director
    		 72,790 2022-06-28 1

    SYKES RICHARD

    • Director
    		 454,108 2022-06-28 1

    FREITAG GREGORY GENE

    • Director
    		 55,153 2022-06-28 1

    ALI-JACKSON KAMIL

    • Director
    		 20,764 2022-06-28 1

    ILIEV ILIAN

    • Director
    		 9,000 2022-06-28 1

    TROCHIMIUK JANETTA PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 0 2021-09-30 0

    BLOOMQUIST DELYLE W

    • SEE REMARKS
    		 798,911 2021-06-16 0

    VAN VOORHEES SETH CHIEF FINANCIAL OFFICER

    • Officer
    		 17,647 2021-06-15 0

    KING MICHAEL N. INTERIM CFO

    • Officer
    		 50,000 2020-12-08 0

    SAIK ANDREW CHIEF FINANCIAL OFFICER

    • Officer
    • Director
    		 42,549 2020-02-14 0

    LOUGHLIN JAMES J

    • Director
    		 0 2019-06-28 0

    MIDDLEKAUFF W BRADFORD SENIOR VP, GC AND SECRETARY

    • Officer
    		 73,770 2019-03-18 0

    BLECH ISAAC

    • Director
    		 No longer subject to file 2019-03-15 0

    BARER SOL J

    • Director
    		 678,075 2019-03-15 0

    CRANE ROSEMARY A

    • Director
    		 No longer subject to file 2019-03-15 0

    SPIEGEL ROBERT J.

    • Director
    		 48,661 2019-03-15 0

    RATCLIFFE LIAM

    • Director
    		 No longer subject to file 2019-03-15 0

    LEUTHNER BRIAN A PRESIDENT AND CEO

    • Officer
    • Director
    		 No longer subject to file 2019-03-15 0

    MACDONALD R. LOCH

    • Director
    		 No longer subject to file 2019-03-15 0

    WYANT ALYSSA SVP REGULATORY AFFAIRS

    • Officer
    		 No longer subject to file 2018-08-15 0

    MARCHIO ALBERT N II CHIEF ACCOUNTING & ADM OFFICER

    • Officer
    		 0 2018-08-14 0

    FALECK HERBERT J CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-08-14 0

    CONTI KURT G

    • Director
    		 1,113,961 2018-03-23 0

    BRENNAN DANIEL CHIEF OPERATING OFFICER

    • Officer
    		 0 2018-03-01 0

    HEALY JAMES

    • Director
    		 0 2017-06-20 0

    YAMAN ALPASLAN V.P., TECHNICAL OPS. & MFG.

    • Officer
    		 0 2017-03-13 0

    EINHORN ANDREW J. CHIEF FINANCIAL OFFICER

    • Officer
    		 126,815 2017-03-01 0

    RATCLIFFE LIAM

    NEW LEAF VENTURES III, L.P.

    NEW LEAF VENTURE ASSOCIATES III, L.P.

    NEW LEAF VENTURE MANAGEMENT III, L.L.C.

    NEW LEAF VENTURE PARTNERS, L.L.C.

    • Director
    		 1,172,434 2016-06-21 0

    RATCLIFFE LIAM

    NEW LEAF VENTURE PARTNERS, L.L.C.

    • Director
    		 0 2016-06-21 0

    VAISH RENU V.P., GLOBAL REG. AFFAIRS

    • Officer
    		 5,350 2016-06-16 0

    HOVE ANDERS D

    • Director
    		 0 2015-09-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 22:15:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 21:45:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 21:15:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 20:45:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 20:15:04 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 19:45:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 19:15:04 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 18:45:04 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 18:15:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 17:45:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 17:15:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 16:45:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 16:15:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 15:45:03 UTC 3.6783 1.1417 300000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 15:15:03 UTC 3.6783 1.1417 250000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 14:45:03 UTC 3.6783 1.1417 600000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 14:15:03 UTC 3.6783 1.1417 600000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 13:45:03 UTC 3.3818 1.1882 600000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 13:15:04 UTC 3.3818 1.1882 600000
    PDS BIOTECHNOLOGY CORP PDSB 2023-03-24 12:45:03 UTC 3.3818 1.1882 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments